MedPath

Metalloproteinases and Recurrent Corneal Erosion Syndrome

Completed
Conditions
Recurrent Corneal Erosion Syndrome
Interventions
Other: in vitro immuno-histo-chemical analysis of corneal epithelium
Registration Number
NCT02891694
Lead Sponsor
Fondation Ophtalmologique Adolphe de Rothschild
Brief Summary

Recurrent corneal erosion (RCE) syndrome can be observed either in the context of a dystrophy of the basement membrane or following corneal trauma. This syndrome is characterized by recurrent episodes of ocular pain more or less associated with localized separations between the outer epithelium and the epithelial basal lamina (basement membrane) because of anchorage abnormalities between these two corneal layers. This could be the result of an increased expression of metalloproteinases cleaving the hemidesmosomes which anchor epithelium to the basement membrane.

The investigators hypothesis is that episodes of RCEs are favored by a hyper- expression of matricial metalloprotease 9 (MMP-9) induced by EMMPRIN and Galectin-3. The identification of such induction could lead to development of therapeutics inhibiting EMMPRIN and Galectin- 3 in the RCE syndrome.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
19
Inclusion Criteria
  • Age > 18 years old
  • Recurrent Corneal Erosion Syndrome, with - failure of medical treatment and therapeutic photokeratectomy scheduled
  • Photorefractive surgical keratectomy (control patients)
Exclusion Criteria
  • Opposition to participation in the study
  • Known pregnancy or breast-feeding patient
  • No medical insurance coverage

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
control patients (refractive surgery)in vitro immuno-histo-chemical analysis of corneal epithelium-
recurrent corneal erosionin vitro immuno-histo-chemical analysis of corneal epithelium-
Primary Outcome Measures
NameTimeMethod
expression of the Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) in epithelial cellsbaseline
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Fondation Opthalmologique A de Rothschild

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath